Reducing CVD Risk in the Patient with High Triglycerides and Metabolic Syndrome or DM-2


Reducing CVD Risk in the Patient with High Triglycerides and Metabolic Syndrome or DM-2

Topic: Cardiology
Relevant Terms: Diabetes Mellitus, Endocrinology, Lipid Management
Primary Audience: Cardiologists; Internists; Lipidologists; Other Healthcare Professionals; Pharmacists; Registered Nurses; Registered Dietitians
Launch Date: 06-Aug-12
Credits: AMA PRA Category 1 Credit
0.8 ACPE contact hour
0.8 ANCC contact hour
1 CDR continuing professional education unit
Expiration Date: The accreditation for this activity has expired.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe the relationship of atherogenic lipids in the setting of mixed dyslipidemia in patients with metabolic syndrome or type 2 diabetes mellitus;
  2. Assess the potential of new and emerging therapeutic approaches to manage hypertriglyceridemic states;
  3. Affect the management of patients with hypertriglyceridemia in patients with metabolic syndrome or type 2 diabetes mellitus using guideline recommendations and evidence-based treatment.
  4. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families


    See Faculty section below for a complete list of faculty.
    Target Audience
    This activity is designed for cardiologists, internists, lipidologists, and other healthcare professionals involved in the treatment of patients at risk of cardiac events.

    Criteria for Success
    Statements of credit will be awarded based on the participant's successful completion of the post-test with a score of 70% or better and the activity evaluation form at If you have questions about this CME/CE activity, please contact the NLA at Please claim credit by August 5, 2013.

    Commercial Support
    This activity is supported by an unrestricted educational grant from Amarin Corporation plc.
    Credit Designation

      CME credit provided by the National Lipid Association


    The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. The National Lipid Association designates this online activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
    Physician Assistants

    NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
     CE Credit provided by Postgraduate Institute for Medicine

    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Universal Activity Number – 0809-9999-12-244-H01-P (Application)
    Postgraduate Institute for Medicine designates this continuing education activity for 0.8 contact hour (0.08 CEU) of the Accreditation Council for Pharmacy Education.
    Initial Release Date (live symposium): June 1, 2012
    If you received ACPE credit for 0809-9999-12-175-L-1-P, you are not eligible to receive ACPE credit for this activity.
    This educational activity for 0.8 contact hour is provided by Postgraduate Institute for Medicine.
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
    This program has been approved by the Commission on Dietetic Registration (CDR) for 1.0 CPEU. Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education unit (CPEU) for completion of this program/material.

    Program Chairman
    Eliot A. Brinton, MD
    Director, Atherometabolic Research
    Utah Foundation for Biomedical Research

    Dr. Brinton obtained his MD from the University of Utah, trained in internal medicine at Duke University, and in endocrinology at the University of Washington. He has been on the faculty of the Rockefeller University, Wake Forest University, the University of Arizona, and the University of Utah. He served for seven years as Chief of the Section of Metabolism, Endocrinology and Nutrition at the Phoenix VA Medical Center, where he was also President of the Phoenix Cross-town Endocrine Society and the Arizona Atherosclerosis Club. He served for 8 years as Director of the Metabolism Section of Cardiovascular Genetics and Associate Professor at the University of Utah School of Medicine in Salt Lake City. He served as President of the Pacific Lipid Association and founding board member of both the National Lipid Association and of the American Board of Clinical Lipidology. In 2012 he shared, with Jan L. Breslow, MD of the Rockefeller University, the Robert I. Levy Award for excellence in lipoprotein metabolism research from the Kinetics and Metabolism Society. Currently, he serves as an editor of Lipids Online, assistant editor of the Journal of Obesity and on the editorial boards of the Journal of Clinical Lipidology, Lipids Online, the Journal of Managed Care Pharmacy, and Clinical Lipidology. He is currently Vice President of the American Board of Clinical Lipidology, President of the Utah Atherosclerosis Society, President of the Utah Lipid Center, and Director of Atherometabolic Research of the Utah Foundation for Biomedical Research in Salt Lake City, Utah.
    Harold E. Bays, MD
    Medical Director and President
    Louisville Metabolic and Atherosclerosis Research Center

    Dr. Bays is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC) in Louisville, Kentucky. He earned his medical degree, completed his internship and residency in internal medicine, and received his fellowship in endocrinology and metabolism at the University of Louisville School of Medicine. Dr. Bays has served as an Investigator in over 400 Phase I - IV clinical trials for treatments for high cholesterol and other dyslipidemias, obesity, diabetes mellitus, hypertension, osteoporosis, and other metabolic and hormonal disorders. He has written, or served as a contributing author for, over 150 scientific manuscripts and book chapters, and authored over 100 scientific abstracts. His publications have appeared in such peer-reviewed journals as the New England Journal of Medicine, Obesity/Obesity Research, Journal of Clinical Endocrinology and Metabolism, and Cell Metabolism. Dr. Bays originated the term "adiposopathy" ("sick fat"), defined as pathogenic adipose tissue promoted by positive caloric balance and sedentary lifestyle in genetically and environmentally susceptible patients. He has published several manuscripts on the adipocentric paradigm wherein pathogenic adipose tissue represents a rational, unifying cause of excessive fat-related metabolic diseases. Dr. Bays is the past Chairman of the American Association of Clinical Endocrinologists (AACE) Task Force on Pathogenic Adipose Tissue. He has served as an expert manuscript reviewer for over 60 scientific medical journals, including the Journal of the American Medical Association (JAMA), The Lancet, Archives of Internal Medicine, International Journal of Obesity, and Annals of Internal Medicine.
    W. Virgil Brown, MD
    Professor Emeritus, Medicine
    Emory University School of Medicine

    Dr. Brown is Professor Emeritus, Medicine at Emory University School of Medicine in Atlanta, Georgia. He earned his medical degree at Yale University School of Medicine, completed his training in internal medicine at Johns Hopkins, and completed a fellowship in endocrinology and metabolism at Yale-New Haven Hospital. Along with his collaborators, Dr. Brown first isolated three of the apolipoproteins (Apo CI, CII and CIII) from human blood and helped define the role of the lipase enzymes in breaking down triglycerides so they could be removed from the bloodstream by the various organs of the body. His studies also helped us understand how various dietary changes and medications alter the metabolism of lipoproteins to correct high levels of cholesterol. Dr. Brown has published over 300 manuscripts in the medical literature. He has served the American Heart Association as a member of several research review committees, as Chairman of the Nutrition Committee, and as Vice Chairman for the Education and Community Program Committee. Dr. Brown served as National AHA President (1991-1992). In 1996, he received the "Gold Heart Award," the highest honor given by the American Heart Association for service to its mission over a lifetime. In 1998-1999, he served as the first President of the Southeast Lipid Association; as the first President of the National Lipid Association (2002-2004) and as President of the National Board of Clinical Lipidology (2004-2008). He is the Editor of the Journal of Clinical Lipidology, and current President of the International Atherosclerosis Society by vote of leadership in 52 National Societies.
    Terry A. Jacobson, MD
    Professor of Medicine
    Director, Office of Health Promotion and Disease Prevention
    Emory University

    Dr. Jacobson is a Professor of Medicine and the Director of the Office of Health Promotion and Disease Prevention at Emory University in Atlanta, Georgia. He also serves as Co- Director of the Lipid and Cardiovascular Risk Reduction Program at Grady Health Systems. A graduate Cornell University Medical College, Dr. Jacobson interned at New York University Medical Center/Bellevue Hospital, and completed a Robert Wood Johnson Clinical Scholar's Fellowship at the University of Pennsylvania. Dr. Jacobson has clinical and research expertise in hyperlipidemia, the nutrition and drug management of hypercholesterolemia, coronary heart disease (CHD) risk reduction, and translation of cardiovascular prevention into practice. Dr. Jacobson has lectured and published extensively in the field of hypercholesterolemia, CHD risk modification, cost-effectiveness, lipid drug safety, and the dietary and pharmacologic treatment of hyperlipidemia. Since 1990, he has published numerous articles in the Journal of the American Medical Association, the American Journal of Cardiology, Archives of Internal Medicine, Annals of Internal Medicine, and others. As an invited speaker at many national and international meetings, he has given presentations on topics ranging from drug therapy for dyslipidemia to new directions in CHD prevention. Dr. Jacobson currently serves on the National Advisory Board of the Agency for Healthcare Research and Quality, the Board of the Southeast Lipid Association, and the National Lipid Association Task Force on Drug Safety. He also is a founding member of the Cardiovascular and Metabolic Health Foundation and currently serves on its Board of Directors.

    Bays, Harold
    Amarin; Daiichi Sankyo, Inc.; Merck & Co., Inc.
    Contracted Research
    Amarin; Amgen, Inc.; Arena; Boehringer Ingelheim; Cargill Incorporated; California Raisin Board; Esperion; Essentialls; Forest Pharmaceuticals; Gilead; Given; GlaxoSmithKline; Johnson & Johnson, Inc.; Merck & Co., Inc.; Novo Nordisk; Omthera, Inc.; Orexigen; Pfizer Inc.; Proctor & Gamble; Shionogi; Stratum; Takeda Pharmaceuticals North America, Inc.; Trygg, TWI Bio
    Speakers Bureau
    Amarin; Daiichi Sankyo, Inc.; Merck & Co., Inc.
    Brinton, Eliot
    Abbott Laboratories, Inc.; AstraZeneca LP; Merck and Co., Inc.; Daiichi Sankyo, Inc.; Atherotech Diagnostics Lab; Takeda Pharmaceuticals; Kowa Pharmaceuticals America, Inc.; GlaxoSmithKline; Essentialis; Amarin; Arisaph
    Contracted Research
    Amarin; Merck and Co., Inc.; Abbott Laboratories, Inc.
    Speakers Bureau
    Abbott Laboratories, Inc.; AstraZeneca LP; Merck & Co., Inc.; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; Kaneka Pharma America LLC; Takeda Pharmaceuticals; Kowa Pharmaceuticals America, Inc.; GlaxoSmithKline; Boehringer Ingelheim, LipoScience, Inc.
    Brown, W. Virgil
    Advisory Board
    Pfizer Inc.; Cerenis
    Abbott Laboratories, Inc.;  Amgen; Anthera Pharmaceuticals; Bristol-Myers Squibb; Genzyme; LipoScience Inc., ; Merck & Co., Inc.; Regeneron
    Speakers Bureau
    Abbott Laboratories, Inc.; LipoScience, Inc.; Merck & Co., Inc.
    Jacobson, Terry
    Amarin; AstraZeneca LP; Abbott Laboratories, Inc.; GlaxoSmithKline; Merck & Co., Inc.
    Nothing to Disclose
    PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Disclosure Declaration
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.

    System Requirements
    To view this educational activity you will need one of the following web browsers: Google Chrome for Windows, Mac, or Linux; Internet Explorer 7.0+ for Windows; Mozilla 1.4+ for Windows, Mac, or Linux; Firefox 3.5+ for Windows, Mac, or Linux; or Safari 4.0+ for Mac. Adobe Flash plug-in 10.0 or greater.